Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Recurrence 1Lymphoma, T-Cell, Cutaneous 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × sapacitabine × Clear all
NCT00590187 2024-06-04

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Cyclacel Pharmaceuticals, Inc.

Phase 2 Completed
105 enrolled 11 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01303796 2022-06-22

SEAMLESS

Cyclacel Pharmaceuticals, Inc.

Phase 3 Completed
482 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01211457 2019-07-16

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Cyclacel Pharmaceuticals, Inc.

Phase 1/2 Unknown
65 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡